olopatadine / Generic mfg. - LARVOL DELTA

Clinical Insights into Mometasone furoate/Olopatadine Combination Therapy (EAACI 2025) - "Sponsored By Menarini."

Clinical • Combination therapy • Allergic Rhinitis • Immunology

Onset of Action (OOA) and Efficacy of Azelastine Hydrochloride 0.15% Nasal Spray (AZNS) on Allergy Symptoms in an Environmental Exposure Chamber (EEC) Compared to Placebo (PL) and Mometasone Furoate/Olopatadine Hydrochloride NS (MFONS) (EAACI 2025) - No abstract available

Clinical • Allergy • Immunology

Ranking the Efficacy of Topical Treatments for Ocular Allergy: A Network Meta-Analysis of Current Evidence. (PubMed, Ocul Surf) - "This network meta-analysis provides strong evidence supporting condition-specific treatment approaches in ocular allergies. Newer antihistamines, particularly Olopatadine, are most effective for mild-moderate conditions, while immunomodulators, especially Tacrolimus, show superior efficacy in severe cases. These findings provide clear evidence-based hierarchies for clinical decision-making in the management of different types of allergic conjunctivitis."

Journal • Retrospective data • Allergy • Conjunctivitis • Dry Eye Disease • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Stability and Efficacy of Mucoadhesive Eye Drops Containing Olopatadine HCl: Physicochemical, Functional, and Preclinical In Vivo Assessment. (PubMed, Pharmaceutics) - "In vivo, OCH-SH and OCH-HPG-SH drops provided prolonged antipruritic and analgesic effects compared to the reference product. Polysaccharide-based innovative formulations improve OCH retention, enhancing therapeutic efficacy and patient compliance in the treatment of allergic conjunctivitis."

Journal • Preclinical • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Pain

Direct-to-consumer customized nasal sprays for allergy relief: A market overview (COSM 2025) - "Both share three active ingredients: triamcinolone, ipratropium, and oxymetazoline, but differ in the antihistamine included—Allermi uses azelastine, while Nectar uses olopatadine. Allermi and Nectar are currently the only DTC sellers of customized allergy-relief IN sprays. Both emphasize convenience, transparent pricing, and customized spray formulations, with ongoing provider support. Nectar further positions the customized IN spray as a bridge to SLIT."

Allergy • Immunology

The therapeutic effect of IPL on children with refractory seasonal allergic conjunctivitis. (PubMed, BMC Ophthalmol) - "IPL therapy is effective in improving ocular surface symptoms in children with refractory seasonal allergic conjunctivitis, especially in suppressing eye itching, with good results."

Clinical • Journal • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

Application of machine learning assisted multi-variate UV spectrophotometric models augmented by kennard stone clustering algorithm for quantifying recently approved nasal spray combination of mometasone and olopatadine along with two genotoxic impurities: comprehensive sustainability assessment. (PubMed, BMC Chem) - "A comprehensive sustainability assessment employed six state-of-the-art tools, including the national environmental method index, complementary green analytical procedure index, analytical greenness metric, blue applicability grade index, carbon footprint analysis, and the red-green-blue 12 metrics. Favorable results across all metrics affirmed the method's eco-friendliness, real-world applicability, and cost-effectiveness, supporting sustainable development goals in pharmaceutical quality control processes."

Journal

Treatment of allergic rhinitis and allergic conjunctivitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Comparison table: Some nasal sprays for seasonal allergic rhinitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Immunology • Inflammation

Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) (PRNewswire) - "Glenmark Pharmaceuticals Inc...has received final approval by the United States Food & Drug Administration (U.S. FDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), determined by the FDA to be bioequivalent to Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), of Alcon Laboratories, Inc. Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the U.S. by Glenmark Therapeutics Inc., USA."

ANDA • Ophthalmology

Comparative assessment of alcaftadine and olopatadine for allergic conjunctivitis: a meta-analysis. (PubMed, Postepy Dermatol Alergol) - "These two groups had similar incidence of adverse events (OR = 0.61; 95% CI = 0.34 to 1.09; p = 0.10). Alcaftadine had better capability to treat allergic conjunctivitis compared to olopatadine."

Journal • Retrospective data • Review • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Comparing the effectiveness of four antihistamines with olopatadine in healthy Thoroughbred horses. (PubMed, J Vet Med Sci) - "The maximum wheal inhibition rate (mean ± SD) of olopatadine (85.3% ± 7.7%) was significantly higher than those of bilastine (51.1% ± 11.8%), rupatadine (55.3% ± 6.6%), and desloratadine (59.8% ± 6.4%), but not levocetirizine (85.4% ± 8.0%). Levocetirizine is expected to have a high antihistamine effect on horses."

Journal • Allergy • Dermatology • Immunology • Urticaria

Probing the Histamine H1 Receptor Binding Site to Explore Ligand Binding Kinetics. (PubMed, J Med Chem) - "Here, fragment 1 (4-(2-benzylphenoxy)-1-methylpiperidine) was used in different fragment growing approaches to mimic the putative binding mode of the long residence time (RT) ligands olopatadine, acrivastine, and levocetirizine at the histamine H1 receptor (H1R). Therefore, the levocetirizine mimics are less sensitive to structural changes. This study illustrates that for H1R, there are several ways to increase RT but the different strategies differ significantly in SKR."

Journal

Implantation of impressive chromatographic and built-in UV spectrophotometry approaches for sustainable Estimation of olopatadine and mometasone in pharmaceuticals; eco-scale and BAGI applications. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "These methods effectively quantify OLO and MOM in their raw materials, different formulations and combined nasal spray, providing a sustainable and reliable approach for pharmaceutical analysis. This work is the first green assessment for the determination of OLO and MOM in pure drug and in the pharmaceutical formulations using less hazard solvent and simple technique."

Journal

Food and bile micelle binding of zwitterionic antihistamine drugs. (PubMed, ADMET DMPK) - "Bilastine (BIL), cetirizine (CET), fexofenadine (FEX), and olopatadine (OLO) were employed as model drugs. Bile micelle and food binding were suggested to cause a negative food effect on the oral absorption of these drugs. However, the AUC ratio was not quantitatively predicted by using FeSSIF + BFH."

Journal

Suppressing Exocytosis of Mast Cells and Its Therapeutic Efficacy for Peritoneal Fibrosis in Rats with Chronic Kidney Failure (KIDNEY WEEK 2024) - "Additionally, using rat models with chronic renal failure (CRF) induced by 5/6 nephrectomy, we actually examined the therapeutic efficacy of these drugs for peritoneal fibrosis complicated with CRF. Among anti-allergic drugs, second-generation antihistamines, such as olopatadine, loratadine and ketotifen, markedly suppressed the increase in the Cm and directly inhibited the exocytotic process, suggesting their potency as mast cell stabilizers. From these results, the activation of mast cells was considered to be responsible for the progression of peritoneal fibrosis in uremic condition. Additionally, the results suggested the therapeutic potency of mast cell stabilizers in the treatment of peritoneal fibrosis in CRF."

Preclinical • Chronic Kidney Disease • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease

Amlexanox reduces new-onset atrial fibrillation risk in sepsis by downregulating S100A12: a Mendelian randomization study. (PubMed, Front Cardiovasc Med) - "Targeting S100A12 identifies five potential small molecule therapeutics: amlexanox, balsalazide, methandriol, olopatadine, and tiboloe. We identified S100A12 as a key gene influencing the new-onset AF in sepsis through immune regulation, presenting considerable diagnostic and predictive value. Notably, amlexanox, by targeting S100A12 emerges as the most clinical relevant intervention for managing new-onset AF in sepsis patients."

Journal • Atrial Fibrillation • Cardiovascular • Infectious Disease • Inflammation • Septic Shock • IL1B • IL6 • S100A12 • TNFA

Keratoconus Cases Associated with Medication Use: A Population-Based Pharmacovigilance Study. (PubMed, J Cataract Refract Surg) - "Overall, several pharmacologic agents were associated with disproportionately high reports of KC, including sex hormones such as progesterone and estradiol, olopatadine, isotretinoin, methylphenidate, spironolactone, antipsychotics such as aripiprazole and risperidone, and dupilumab. These results underscore the need for increased clinical vigilance in monitoring for early signs of KC in patients prescribed these medications. Furthermore, healthcare providers should be aware of the potential drug-related associations for KC, especially in high-risk groups."

Adverse events • Journal • CNS Disorders • Mood Disorders • Ophthalmology • Rheumatology

Development of a Temperature and pH Dual-Sensitive In-Situ Gel for Treating Allergic Conjunctivitis. (PubMed, AAPS PharmSciTech) - "The purpose of this study was to improve the efficacy of olopatadine hydrochloride (OT) in treating allergic conjunctivitis (AC)...The expression levels of IL-13, IL-17, and OVA-IgE in mouse ocular tissues with allergic conjunctivitis treated with TP-gel were significantly reduced. This suggests that TP-gel has the potential to be an effective treatment method for allergic conjunctivitis."

Journal • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology • IL13 • IL17A

Dupilumab-Associated Symblepharon Case Report – Should We Be Monitoring These Patients? (ESCRS 2024) - "He previously had issues taking oral Ciclosporin and topical Ikervis was therefore avoided. Instead, he was given another course of topical steroid (Softacort) with Olopatadine... A common, recognised side effect (>1/100 to <1/10) of Dupilumab is an inflammatory conjunctivitis. It is possible that repeated episodes can lead to symblepharon formation. Based on our reported case, we propose that patients who develop Dupilumab-associated conjunctivitis should be monitored in the eye clinic regularly to monitor for symblepharon formation, with early therapy substitution if appropriate."

Case report • Clinical • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

A Case Of Idiopathic Conjunctival Chemosis: Successful Management With Inferior Conjunctival Cauterisation. (ESCRS 2024) - "He was initially treated with olopatadine 0.2% and dexamethasone 0.1% for possible allergic eye disease, with little effect...Conclusion/Take home message: Our case highlights a simple but effective surgical technique in the management of idiopathic conjunctival chemosis, using inferior conjunctival cauterisation. Furthermore, it considers the important investigations to perform in cases of chemosis."

Clinical • Ophthalmology

Clinically Relevant Characterization and Comparison of Ryaltris and Other Anti-Allergic Nasal Sprays. (PubMed, Pharmaceutics) - "The work aims to investigate technological aspects of Ryaltris (mometasone furoate and olopatadine hydrochloride nasal spray) compared to other commercial anti-allergic nasal products, namely, Dymista (azelastine hydrochloride and fluticasone propionate), Nasonex (mometasone furoate), and Avamys (fluticasone furoate). Finally, the intranasal deposition profile of the commercial formulations was determined using a silicon nasal cast. The results highlight in vitro significant differences in terms of viscosity as well as dissolution rate of the nasal products, with Ryaltris showing a higher viscosity and lower flow compared to other products, which, along with a corticosteroid faster dissolution rate than Dymista, suggest a potential advantage in terms of clinical behavior."

Journal

Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC) (PRNewswire) - "Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce it has launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC); compare to the active ingredient in Pataday Twice Daily Relief."

Launch US • Ophthalmology

Green and sensitive detection of olopatadine in aqueous humor using a signal-on fluorimetric approach: GREEnness assessment. (PubMed, Luminescence) - "Furthermore, it demonstrates robust performance in determining OLP in artificial aqueous humor with a percentage recovery of 99.05 ± 1.51, with minimal interference from matrix interferents. Moreover, the greenness of the described method was evaluated."

Journal • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Efficacy, safety, and serum cytokine modulation by olopatadine hydrochloride and desloratadine citrate disodium combination therapy in urticaria. (PubMed, Am J Transl Res) - "The combination of OLP and DES is an effective and safe treatment option for urticaria, significantly improving serum cytokine profiles, alleviating symptoms, and reducing recurrence risk."

Combination therapy • Journal • Dermatology • Fatigue • Immunology • Pain • Urticaria • Xerostomia • IFNG • IL2 • IL4